Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aliskiren + eplerenone + telmisartan
- Development stage
- Unknown
- Lead developer
- Medical University of Gdańsk
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Aliskiren + eplerenone + telmisartan is a combination therapy regimen investigated for the treatment of non-diabetic proteinuric chronic kidney disease (CKD). The regimen utilizes three distinct mechanisms to inhibit the renin-angiotensin-aldosterone system (RAAS): telmisartan acts as an angiotensin II receptor blocker (ARB), aliskiren serves as a direct renin inhibitor, and eplerenone functions as a mineralocorticoid receptor antagonist (MRA). By targeting multiple points in the RAAS cascade, the combination aims to achieve more complete suppression of the system than monotherapy or dual blockade, potentially leading to greater reductions in proteinuria and improved renal outcomes. This specific triple-blockade approach was evaluated in a Phase 4 clinical trial sponsored by the Medical University of Gdansk.
- Other names
- aliskiren, eplerenon, telmisartan
02
Targets
REN (Renin)AGTR1 (Angiotensin II Type-1 receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on aliskiren + eplerenone + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aliskiren + eplerenone + telmisartan.